TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9564446
Drug: Moderately suprathreshold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately suprathreshold dose
Study: 24345834
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (200 mg/day)
Study: 15723745
Drug: Fish Oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish Oil (FO) - 30 mL/d providing 4.9 g of eicosapentaenoic acid and 3.2 g of docosahexanoic acid for 4 weeks
Study: 15723745
Drug: Melatonin (MLT)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin (MLT) - 18 mg/d for 4 weeks
Study: 15723745
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Fish Oil and Melatonin for the next 4 weeks
Study: 10397212
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-Acetylcysteine (NAC) treatment (150 mg/kg bolus followed by continuous infusion of 12 mg/kg/hr)
Study: 20460477
Drug: docetaxel plus
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel plus ASA404 1,200 mg/m2 (A-D)
Study: 20460477
Drug: docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 75 mg/m2 alone (D)
Study: 19013751
Drug: Ropivacaine infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine infiltration (40 ml of ropivacaine 4.75 mg/ml)
Study: 15823991
Drug: Surface electrical
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surface electrical stimulation (ES) for 20 min once daily, 6 days per week for 1 month
Study: 12779107
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic (Hurricaine Dry Handle Swab, 20% benzocaine)
Study: 30829753
Drug: Combined CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined CO2 laser followed by topical 5‐fluorouracil (5‐FU) application
Study: 30829753
Drug: Combined CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined CO2 laser followed by topical verapamil hydrochloride application
Study: 30829753
Drug: CO2 laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 laser monotherapy
Study: 24596911
Drug: Denture adhesive
Normalized name: DENTURE ADHESIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denture adhesive cream
Study: 23152962
Drug: PEG-only 0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-only 0.7 g/kg/day in 2 divided doses
Study: 23152962
Drug: PEG-EL 6.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-EL 6.9 g in 1-4 sachets according to age for 4 weeks
Study: 20364686
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clinical homeopathy and dynamic electrical neurostimulation (DENS)
Study: 18681276
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) at a concentration of 25 mg/mL applied topically for 1 minute, 4 times after tendon repair
Study: 12934466
Drug: Anti-cytokine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-cytokine therapy targeting TNF-alpha, IL-1, and IF-gamma
Study: 12934466
Drug: New low-molecular
Approvals — FDA: no, EMA: no, PMDA: no
Description: New low-molecular inhibitors of cytokines
Study: 12934466
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anti-cytokines with other antirheumatic drugs
Study: 11096191
Drug: Tuberculin (PPD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuberculin (PPD) test (0.1 ml of PPD, 2 TU)
Study: 1443741
Drug: Intravenous sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sufentanil 10 micrograms
Study: 31913911
Drug: Amisulpride 10
Normalized name: amisulpride 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride 10 mg (given twice, 2 hours apart)
Study: 31913911
Drug: Amisulpride 10
Normalized name: amisulpride 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride 10 mg and Ondansetron 4 mg (given simultaneously)
Study: 31725826
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of oxaliplatin-based adjuvant chemotherapy
Study: 31725826
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of oxaliplatin-based adjuvant chemotherapy
Study: 30332403
Drug: Praziquantel (PZQ)
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel (PZQ) at a single dose of 40 mg/kg
Study: 26179124
Drug: Prednisone (initiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (initiated at 10 mg every other day, titrated to a maximum of 40 mg/day over 16 weeks)
Study: 22407196
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (IB); nebulized, administered at 30-minute intervals for 2 hours
Study: 22407196
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (MgSO4); combined nebulized and intravenous bolus, administered at 30-minute intervals for 2 hours
Study: 22950884
Drug: Transparent decision
Normalized name: TRANSPARENT DRESSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transparent decision model for rating drug-drug interactions
Study: 19803687
Drug: THC 0.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC 0.0 mg
Study: 19803687
Drug: THC 29.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC 29.3 mg
Study: 19803687
Drug: THC 49.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC 49.1 mg
Study: 19803687
Drug: THC 69.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC 69.4 mg
Study: 12394655
Drug: Mediterranean diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean diet + statin treatment
Study: 2277567
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL 1% lidocaine solution injected through the catheter on the tube.
Study: 2277567
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL 2% lidocaine solution injected through the catheter on the tube.
Study: 31371228
Drug: Adjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant systemic chemotherapy alone
Study: 26504148
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg/day for 14 days)
Study: 15759538
Drug: Barthel Activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barthel Activities of Daily Living Index
Study: 11983043
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (0.15 mg/kg in 3 ml saline)
Study: 2539186
Drug: Clotrimazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole (200 mg intravaginal daily for 3 days)
Study: 23377324
Drug: Monopolar radiofrequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monopolar radiofrequency system (Pellevé S5 Wrinkle Treatment Generator)
Study: 21834655
Drug: Tailored footwear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored footwear programme (player education, prescription of footwear, frequent rotation of footwear)
Study: 20057896
Drug: Rosuvastatin (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (specific dosage and duration not mentioned)
Study: 15688690
Drug: Dan Zhi
Normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dan Zhi Xiao Yao Yin combined with auricular-point-pressing therapy
Study: 18246677
Drug: Routine western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine western drugs
Study: 23167405
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus 1-week continuous infusion of 5-FU (1000 mg/d) and heparin (5000 IU/d) infusion initiated from the day of surgery for 7 consecutive days (study group)
Study: 7283808
Drug: 0.25% dipivefrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% dipivefrin twice a day plus 0.25% echothiophate iodide twice a day
Study: 7283808
Drug: 2% epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% epinephrine hydrochloride twice a day plus 0.25% echothiophate iodide twice a day
Study: 22264722
Drug: Valsartan (V;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (V; 160 then 320 mg/day)
Study: 22264722
Drug: Carvedilol (C;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (C; 20 then 40 mg/day)
Study: 22264722
Drug: Lisinopril (L;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (L; 40 mg/day)
Study: 19644849
Drug: Golimumab 100
Normalized name: golimumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab 100 mg plus placebo
Study: 19066176
Drug: Golimumab 50
Normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab 50 mg plus methotrexate
Study: 19066176
Drug: Golimumab 100
Normalized name: golimumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab 100 mg plus methotrexate
Study: 17878518
Drug: 70-gene signature
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 70-gene signature (Mammaprint®™) for selecting patients for adjuvant chemotherapy
Study: 17878518
Drug: Conventional clinicopathological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional clinicopathological criteria for adjuvant chemotherapy
Study: 16279899
Drug: Induction-dose triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction-dose triple therapy (IDTT) with IFN-alpha2b + RBV + AMD for 24 weeks
Study: 2448561
Drug: Haemodilution (by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemodilution (by venesection and replacement of the same volume of dextran 40 in saline solution)
Study: 28146219
Drug: ABBM-PRF combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBM-PRF combination
Study: 26788875
Drug: Santes® (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Santes® (two suppositories per day for 4 months, first two months simultaneous to RT and BRT)
Study: 26788875
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment during RT)
Study: 26788875
Drug: Santes® (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Santes® (two suppositories per day for 4 months)
Study: 21808190
Drug: Triazolam (0.06,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.06, 0.12 and 0.25 mg/70 kg)
Study: 21808190
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of progesterone and triazolam
Study: 16641126
Drug: Montelukast (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5 mg chewable tablets administered once daily in the evening)
Study: 15613121
Drug: Structured weekly
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured weekly educational telephone intervention (8 weeks)
Study: 6140906
Drug: Ipecac (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipecac (30 mL, repeated if vomiting not induced)
Study: 6140906
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (60 g) with magnesium sulfate (MgSO4)
Study: 6140906
Drug: Control (aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (aspirin only)
Study: 26553615
Drug: 1 mg/mL
Normalized name: urea 1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/mL histamine
Study: 26553615
Drug: 6 mg/mL
Normalized name: phenol 6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/mL histamine
Study: 23639228
Drug: Pidotimod (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidotimod (800 mg single dose)
Study: 23639228
Drug: Two formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two formulations of pidotimod
Study: 20858104
Drug: Conventional RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional RT plus intracavity hyperthermia (T90 42.5°‐43°C for 50 min twice a week for 7 weeks)
Study: 15113612
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination (FDC) tablet of rifampicin, isoniazid, and pyrazinamide
Study: 15113612
Drug: Standard separate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard separate combination of rifampicin, isoniazid, and pyrazinamide
Study: 12407136
Drug: Artesunate (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (4 mg/kg/day for 3 days)
Study: 7548288
Drug: 0.5% podophyllotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% podophyllotoxin cream (Condyline), applied twice daily for three days in weekly intervals
Study: 7548288
Drug: 20% podophyllin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% podophyllin solution, applied weekly
Study: 7548288
Drug: 0.5% podophyllotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% podophyllotoxin cream (Condyline)
Study: 7548288
Drug: 20% podophyllin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% podophyllin solution
Study: 29507942
Drug: IV methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV methylprednisolone sodium succinate (1000-mg)
Study: 29507942
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (1250-mg)
Study: 27430605
Drug: Preventive intercostal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive intercostal nerve block (ICNB) followed by catheter-based infusion of 0.5% bupivacaine
Study: 27430605
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) analgesia alone
Study: 24913161
Drug: Voriconazole (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole (6 mg/kg IV q12h for 24h followed by 4 mg/kg IV q12h, switched to 300 mg orally q12h as appropriate)
Study: 24913161
Drug: Anidulafungin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anidulafungin (200 mg loading dose followed by 100 mg IV q24h)
Study: 23730580
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate nasal spray and nasal breathing exercise (NBE)
Study: 20547444
Drug: Betamethasone (2x12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (2x12 mg within 24 h)
Study: 12834861
Drug: 1x 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1x 125 mg oral brivudin for 7 days
Study: 12834861
Drug: 5x 800
Normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5x 800 mg acyclovir for 7 days
Study: 11304051
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg elemental zinc (n = 136)
Study: 6823630
Drug: Epidural pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural pethidine 0.75 mg/kg
Study: 6823630
Drug: Intramuscular pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular pethidine 1.5 mg/kg
Study: 31607294
Drug: Decitabine combined
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine combined with half-course pre-excitation treatment
Study: 31607294
Drug: Routine complete
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine complete course pre-excitation treatment (Control)
Study: 24533082
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (25 g; PRO)
Study: 24533082
Drug: Alcohol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (1.5 g·kg body mass⁻¹) co-ingested with protein (ALC-PRO)
Study: 24533082
Drug: Alcohol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (1.5 g·kg body mass⁻¹) co-ingested with carbohydrate (ALC-CHO)
Study: 24533082
Drug: Energy-matched quantity
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy-matched quantity of carbohydrate (25 g maltodextrin; ALC-CHO)
Study: 17419955
Drug: Supportive‐expressive group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive‐expressive group therapy (SEGT)
Study: 11940738
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus hypothermia for 48 hrs
Study: 11940738
Drug: Standard brain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard brain injury treatment
Study: 9639217
Drug: Amnioinfusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amnioinfusion of normal saline (37 degrees C) at 600 ml/h for 1 h, then 180 ml/h until full cervical dilatation or uterine baseline activity reached 20 mm Hg.
Study: 1059709
Drug: Detergent-split subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detergent-split subunit vaccine
Study: 31812490
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (15 minutes twice per day during phototherapy)
Study: 30552112
Drug: Pertuzumab in
Normalized name: pertuzumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertuzumab in combination with trastuzumab and chemotherapy
Study: 30552112
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with trastuzumab and chemotherapy
Study: 16814414
Drug: N-acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (600 mg twice daily)
Study: 11578715
Drug: Tirofiban with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban with unfractionated heparin
Study: 9406135
Drug: Prophylactic use
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic use of pancreatic enzyme-sodium bicarbonate suspension (5 mL containing lipase 2000 FIP units, amylase 1500 FIP units, protease 100 FIP units, and 90 mg NaHCO3)
Study: 8482047
Drug: Endothelin-1 +
Normalized name: nitric oxide synthase endothelial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin-1 + NG-mononmethyl-L-arginine
Study: 8482047
Drug: Endothelin-1 +
Normalized name: nitric oxide synthase endothelial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin-1 + Aspirin (acetylsalicylic acid)
Study: 3025113
Drug: Theophylline therapy
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline therapy (sustained release preparation, TheoDur 200 and 300 mg)
Study: 3025113
Drug: Theophylline therapy
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline therapy (sustained release preparation)
Study: 29127072
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field (PEMF) therapy with a repetition frequency of 2.05Hz and a maximum flux density of 25.3μT (rms)
Study: 24709491
Drug: Trimetazidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (20 mg orally, tid for 7 days)
Study: 24709491
Drug: Control (placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo, 10 mL of sterile water for injection, tid for 7 days)
Study: 18820825
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (continued previous treatment)
Study: 17666353
Drug: Isoflurane inhalation
Normalized name: isoflurane INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflurane inhalation with FGF rate of 1 L/min, setting concentration 1%
Study: 17666353
Drug: Isoflurane inhalation
Normalized name: isoflurane INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflurane inhalation with FGF rate of 1 L/min, setting concentration 2%
Study: 17666353
Drug: Isoflurane inhalation
Normalized name: isoflurane INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflurane inhalation with FGF rate of 2 L/min, setting concentration 1%
Study: 17666353
Drug: Isoflurane inhalation
Normalized name: isoflurane INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflurane inhalation with FGF rate of 2 L/min, setting concentration 2%
Study: 17666353
Drug: Isoflurane inhalation
Normalized name: isoflurane INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflurane inhalation with FGF rate of 3 L/min, setting concentration 1%
Study: 17666353
Drug: Isoflurane inhalation
Normalized name: isoflurane INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflurane inhalation with FGF rate of 3 L/min, setting concentration 2%
Study: 7641897
Drug: Goserelin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin plus HRT (25 micrograms transdermal 17 beta E2 daily and 5 mg medroxyprogesterone acetate orally daily) for 20 weeks
Study: 7641897
Drug: Goserelin alone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin alone, 3.6 mg SC depot every 4 weeks for 24 weeks
Study: 7641897
Drug: Goserelin, 3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin, 3.6 mg SC depot every 4 weeks for 24 weeks, plus HRT
Study: 790943
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections on the same schedule
Study: 30062527
Drug: Ultrasound-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided injection (1 ml of 2% mepivacaine and 40 mg of triamcinolone)
Study: 30062527
Drug: Blind injection
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind injection (1 ml of 2% mepivacaine and 40 mg of triamcinolone)